Latest Adenocarcinoma Stories
Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers — a first step in developing potential therapeutic targets.
Smoking is a well-known risk factor for lung cancer, but about 25% of all lung cancer patients have never smoked. According to this study, a gene fusion event could explain a significant proportion of these lung cancer cases, and may serve as a target for new therapies.
Smoking is a well-known risk factor for lung cancer, but nearly 25% of all lung cancer patients have never smoked.
A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease.
An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.
- A serpent whose bite was fabled to produce intense thirst.